期刊文献+

HPLC-MS/ESI同时测定人血浆中米屈肼和左卡尼汀 被引量:5

Simultaneous HPLC-MS/ESI determination of mildronate and levocarnitine in human plasma
原文传递
导出
摘要 目的:建立一种快速、准确、灵敏的高效液相色谱-质谱(HPLC-MS)法同时测定人血浆中米屈肼和左卡尼汀的浓度。方法:以卡巴胆碱作为内标,血浆样品经蛋白沉淀法处理,用氰基色谱柱(Ultimate XB-CN,4.6 mm×250 mm,5μm)进行分离,以乙腈-30 mmol·L^(-1)醋酸铵水溶液(含0.08%甲酸)(80:20,v/v)为流动相,流速1.0 mL·min^(-1),柱温40℃,柱后分流比为4:1,HPLC-MS/ESI^+法选择性监测准分子离子峰[M+H]^+(米屈肼m/z 147.1,左卡尼汀m/z 162.1,内标卡巴胆碱m/z147.1)。结果:米屈肼、左卡尼汀及内标卡巴胆碱在氰基柱上保留较好,分离完全;米屈肼、左卡尼汀线性范围分别为0.1~30.0μg·mL^(-1)(r=0.9985)和0.4~12.8μg·mL^(-1)(r=0.9994);最低定量限分别为0.1μg·mL^(-1)和0.4μg·mL^(-1);平均萃取回收率均大于80%,方法回收率为92%~114%;日内日间RSD均小于12%。结论:本方法简便准确,可用于同时测定人血浆中米屈肼和左卡尼汀的浓度,考察服用米屈肼对血浆中内源性物质左卡尼汀浓度的影响。 Objective:To establish a high - performance liquid chromatography - electrospray ionization mass spectrometry (HPLC -MS/ESI) method for simultaneous determination of mildronate and levocarnitine in human plasma. Methods:Carbachol was used as the internal standard(IS).The compound and internal standard were exreacted by protein precipitation using acetonitrile.The HPLC separation of the analytes was performed on a Ultimate XB - CN(4.6 mm×250 mm,5μm) column with a column temperature of 40℃.The mobile phase was acetonitrile-water (ammonium acetate:30 mmol·L^-1;formic acid:0.08%)(80:20,v/v).The flow rate was 1.0 mL·min^-1, and the postcolumn splitting ratio was 4:1.Electrospray ionization mass spectrometry(ESI/MS) was used for determination, with positive ion SIM detection of mildronate([M + H]^+,m/z 147.1),levocarnitine([M + H]^+,m/z 162.1) and carbachol([M + H]^+,m/z 147.1).Results:Mildronate,levocarnitine and IS all could be retained well and separated completely on the Ultimate XB - CN column.The calibration curves were linear in the ranges of 0.1 - 30.0μg·mL^-1(r = 0.9985 ) for mildronate and 0.4 - 12.8μg·mL^-1(r = 0.9994 ) for levocarnitine;The limits of detection(LOD) were 0.1μg·mL^-1 for mildronate and 0.4μg·mL^-1 for levocarnitine;The average extraction recoveries for all the two analytes were above 80%;The methodology recoveries were 92%- 114%;The intra - day and inter - day relative standard deviations were less than 12%.Conclusion:The method is accurate and simple for simultaneous determination of mildronate and levocarnitine in human plasma,and can be used to investigate the effect of administed mildronate on the plasma concentration of levocarnitine in human.
出处 《药物分析杂志》 CAS CSCD 北大核心 2010年第4期609-614,共6页 Chinese Journal of Pharmaceutical Analysis
关键词 米屈肼 左卡尼汀 HPLC-MS 血药浓度 mildronate levocarnitine HPLC - MS plasma drug concentration
  • 相关文献

参考文献10

  • 1Shatsky Fred. Should carnitine be added to parenteral nutrition solutions. Nutr Clin Pract ,2000,15 ( 1 ) : 152.
  • 2Dambrova Maija, Liepinsh Edgars, Kalvinsh Ivars. Mildronate : Cardioprotective action through camitine - lowering effect. Trends Cardiovasc Med,2002,12 (6) :275.
  • 3Kirimoto T, Nobori K, Asaka N, et al. Beneficial effect of MET - 88,a gamma- butyrobetaine hydroxylase in hibitor, on energy metabolism in ischemic dog hearts. Arch lnt Pharmacodyn Ther, 1996, 331(2) :163.
  • 4Hayashi Y, MuranakaY, Kirimoto T, et al. Effects of MET - 88, a gamma- butyorbetaine hydroxylase inhibitor, on tissue camitine and lipid levels in rats. Biol Pharrn Bull,2000,23(6) :770.
  • 5Hayashi Y, Tajima K, Kirimoto T, et al. Cardioprotective effects of MET-88 ,a gamma- butyrobetaine hydroxylase inhibitor,on cardiac dysfunction induced by ischemia/reperfusion in isolated rat hearts. Pharmacology,2000,61 (4) :238.
  • 6Liepinsh Edgars, Vilskersts Reinis, Loca Dagnija, et al. Mildronate, an inhibitor of carnitine biosynthesis, induce an increase in gamma -butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol,2006,48 ( 6 ) : 314.
  • 7LU YF, Hu X, Bi KS. Determination of mildronate in human plasma and urine by liquid chromatography - tandem mass spectrometry. J Chromatogr B,2007,852 ( 8 ) :35.
  • 8王大为,武洁,黄厚才,王志刚,胡春萍.LC-MS/MS法测定犬血浆中左卡尼汀[J].药物分析杂志,2008,28(2):207-210. 被引量:4
  • 9Angsten G, Cederblad G, Meurling S. Reference ranges for muscle carnitine concentration in children. Ann Clln Biochem, 2003,40 (4) :404.
  • 10孙永旭,陆丛笑,唐启令,曹玉,薛玉增,万秀霞,王春波.高效液相色谱法同时测定人血浆中左卡尼汀、乙酰左卡尼汀和丙酰左卡尼汀的浓度[J].中国药学杂志,2007,42(18):1425-1428. 被引量:7

二级参考文献14

  • 1ANGSTEN G,CEDERBLAD G,MEURLING S.Reference ranges for muscle carnitine concentration in children[J].Ann Clin Biochem,2003,40(4):404-410.
  • 2LINF.The application of L-carnitine in holo-parenteraL alimentation.中华胃肠道杂志,2003,3(1):42-42.
  • 3ANGELINI C,VERGANI L,MARTINUZZI A.Clinical and biochemical aspects of carnitine deficiency and insufficiency:trans port defects and inborn errors of oxidation[J].Crit Rev Clin Lab Sci,1992,29(34):217-242.
  • 4MARZO A,MARTELLI EA,MANCINELLI A,et al.Protein Binding of tine in L-Carnitine Family Components[M].Participants Papers(Special Issue No Ⅲ).Eur J Drug Metab Pharmacokinet,1991,364-368.
  • 5PACE S,LONGO A,TOON S,et al.Pharmacokinetics of propionyl-L-carnitine in humans:evidence for saturable tubular reabsorption[J].Br J Clin Phammcol,2000,50(5):441-448.
  • 6HOPPEL C.The role of carnitine in normal and altered fatty acid metabolism[J].Am J Kidney Dis,2003,41(4):4-12.
  • 7A LONGO,G.BRUNO,S.CURTI,et al.Determination of L-carnitine,acetyl-L-carnitine andpropionyl-Lcarnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene[J].J Chromatography B,1996,686:129-139.
  • 8LAURENCE VERNEZ,MICHAEL DICKENMANN,JURG STEIGER,et al.Effect of L-carnitine on the kinetics of carnitine,acylcarnitines and butyrobetaine in long-term haemodialysis[J].Nephrol Dial Transplant,2006,21:450-458.
  • 9Fred Shatsky. Should carnitine be added to parenteral nutrition solutions. Nutr Clin Pract ,2000 ,15 : 152
  • 10Longo A, Bruno G, Curti S, et al. Determination of L - camitine, acetyl -L - carnitine and propionyl - L - camitine in human plasma by high performance liquid chromatography after pre - column derivatization with 1 - aminoanthracene. J Chromatogr B, 1996,686 : 129

共引文献8

同被引文献28

  • 1张吟,陈一农,陈文发.固相萃取-高效液相色谱法测定人血清中莫西沙星浓度[J].中国医院药学杂志,2007,27(4):481-483. 被引量:24
  • 2孙永旭,陆丛笑,唐启令,曹玉,薛玉增,万秀霞,王春波.高效液相色谱法同时测定人血浆中左卡尼汀、乙酰左卡尼汀和丙酰左卡尼汀的浓度[J].中国药学杂志,2007,42(18):1425-1428. 被引量:7
  • 3国家食品药品监督管理局.JX20060188国家药品标准.
  • 4Sesti C,Simkhovich BZ,Kalvinsh I. Mildronate,a novel fatty acid oxidation inhibitor and antianginal agent,reduces myocardial infarct size without affecting hemodynamics[J].Journal of Cardiovascular Pharmacology and therapeutics,2006,(03):493-499.
  • 5Dambrova M,Licpinsh E,Kalvinsh I. Mildronate:Cardioprotective Action through Carnitine-Lowering Effect[J].Trends in Cardiovascular Medicine,2002.275-279.
  • 6Yoshisue K,Yamamoto Y,Yosbida K. Pharmacokineties and biological fate of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate (MET-88),a novel cardioprotective agent,in rats[J].Drug Metabolism and Disposition,2000,(06):687-694.
  • 7梁文权.生物药剂学与药动学[M]北京:人民卫生出版社,2000253-255.
  • 8Lv YF,Hu X,Bi KS. Determination of mildronate in hu-man plasma and urine by liquid chromatography-tandemmass spectrometry[J]. J Chromatogr B Analyt Technol Bio-med Life to', 2007,852(1/2):35.
  • 9Peng Y,Yang J,Wang Z,et al. Determination of mildro-nate by LC-MS/MS and its application to a pharmacoki-netic study in healthy Chinese volunteersfJ]. J Chro-matogr B Analyt Technol Biomed Life Sci, 2010,878 (5/6):551.
  • 10国家药品标准.左卡尼汀注射液[S].国家食品药品监督管理局,WS1-(X-023)-2005Z.

引证文献5

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部